Up to now there have been two MenB vaccines licensed in the United States. 

Both MenB-FHbp (Trumenba, Pfizer) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals) were for patients aged 10 to 25 years.  These vaccines didn’t cover younger children and infants who can also be stricken with serogroup B meningococcal meningitis.  Now though the CDC’s Advisory Committee on Immunization Practices (ACIP) recommends the MenB-FHbp vaccine for infants.  Consult with your physician so your children can be protected.

Read the full story here